Ischemic Myocardial Articles & Analysis
5 news found
The PACIFIC-STROKE2 and PACIFIC-AMI3 Phase IIb trials compared the safety and efficacy of asundexian with placebo in patients following acute non-cardioembolic ischemic stroke or acute myocardial infarction (AMI), respectively. Both trials showed consistent safety results for asundexian comparable to placebo arm, regardless of background therapy. ...
ByBayer AG
The primary efficacy endpoint was a composite of MALE and MACE, ie. acute limb ischemia, major amputation of a vascular etiology, heart attack (myocardial infarction, MI), ischemic stroke or cardiovascular death. The primary safety outcome was major bleeding according to the Thrombolysis in Myocardial Infarction (TIMI) classification. ...
ByBayer AG
” "In addition to our critically important autologous cell therapies being studied for ischemic heart failure and chronic myocardial ischemia with refractory angina, the FDA's acceptance of this IND for patients recovering from ARDS is an important milestone in the development of our allogeneic mesenchymal stem cell therapy platform and validation for its ...
Early detection of high risk plaque phenotypes holds the promise to prevent myocardial infarction and ischemic stroke by enabling personalized therapeutics BOSTON–(BUSINESS WIRE)–Elucid, a medical technology company developing AI software to enable cardiovascular disease detection, and researchers at the Karolinska Institutet (Stockholm, Sweden), ...
ByElucid
” The ALIVE Trial is designed to demonstrate the safety and effectiveness of the Revivent TC System, a hybrid, minimally invasive transcatheter procedure designed to treat patients suffering from ischemic cardiomyopathy by reshaping and restoring the left ventricle (LV). ...